Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2015

Collaborative Arrangements.

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2015		2014		2015		2014
Mylan	$	25	$	—	$	19,124	$	—
SciClone Pharmaceuticals	2,950		—		2,950		—
R-Pharm	2,009		2,110		2,031		2,110
Other	26		3		26		3
Total revenue from collaborative arrangements	$	5,010	$	2,113	$	24,131	$	2,113

Summary of reductions to R&D expenses related to the reimbursement payments

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2015		2014		2015		2014
Mylan	$	11,610	$	—	$	15,742	$	—
Alfa Wassermann	367		20		789		112
R-Pharm	277		2		277		22
Total reduction to R&D expense	$	12,254	$	22	$	16,808	$	134